Evidence map›Paper›PMID 31101634›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2019

The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice.

Laura Riolobos, Ekram A Gad, Piper M Treuting, Andrew E Timms, Elliot A Hershberg, Lauren R Corulli, Erin Rodmaker, Mary L Disis

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. The European respiratory journal · 2022
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laura RiolobosUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington. lriolobo@uw.edu.
Ekram A GadUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Piper M TreutingDepartment of Comparative Medicine, University of Washington, Seattle, Washington.ORCID 0000-0002-1812-1519
Andrew E TimmsCenter for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, Washington.
Elliot A HershbergUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Lauren R CorulliUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Erin RodmakerUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.ORCID 0000-0001-8924-1879
Mary L DisisUW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Infectious Disease Research Institute · USSeattle Children's Hospital · USUniversity of Washington · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
NCATS NIH HHS KL2 TR002317NCATS NIH HHS UL1 TR002319NCI NIH HHS HHSN261201200013I
6 · The paper itself

Abstract

In order to translate new treatments to the clinic, it is necessary to use animal models that closely recapitulate human disease. Lung cancer develops after extended exposure to carcinogens. It has one of the highest mutation rates of all cancer and is highly heterogenic. Topical treatment with N-nitrosotris-(2-chloroethyl)urea (NTCU) induces lung squamous cell carcinoma (SCC) with nonsynonymous mutation rates similar to those reported for human non-small cell lung cancer. However, NTCU induces lung cancer with variable efficacy and toxicity depending on the mouse strain. A detailed characterization of the NTCU model is needed. We have compared the effect of three different NTCU doses (20, 30, and 40 mmol/L) in female and male of NIH Swiss, Black Swiss, and FVB mice on tumor incidence, survival, and toxicity. The main findings in this study are (1) NIH Swiss mice present with a higher incidence of SCC and lower mortality compared with Black Swiss and FVB mice; (2) 30 mmol/L NTCU dose induces SCC at the same rate and incidence as the 40 mmol/L dose with lower mortality; (3) female mice present higher grade and incidence of preinvasive lesions and SCC compared with males; (4) NTCU-induced transformation is principally within the respiratory system; and (5) NTCU treatment does not affect the ability to elicit a specific adaptive immune response. This study provides a reference point for experimental designs to evaluate either preventive or therapeutic treatments for lung SCC, including immunotherapies, before initiating human clinical trials.

Indexed as

AnimalsCarcinogensCarcinoma, Squamous CellCarmustineCell Transformation, NeoplasticDose-Response Relationship, DrugFemaleIncidenceLungLung NeoplasmsMaleMiceNeoplasms, ExperimentalRisk FactorsSex FactorsCarcinogensCarmustineN-nitroso-tris-chloroethylurea

Identifiers

PMID31101634
PMCPMC7687913
OpenAlexW2946034940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.